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S U M M A R Y
Objective: The identiﬁcation of the optimal agent for administration via the respiratory tract when
treating pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
Methods: A murine model of acute CRAB pneumonia was established by intratracheal (i.t.) inoculation
with 2.5  107 colony-forming units (CFU) of A. baumannii strain Ab396 plus 10% porcine mucin. After
4 h the infected BALB/c mice were treated intratracheally with 25 ml of either 0.85% saline (control
group), colistimethate sodium (CMS) (166 666 U/kg, CMS group), imipenem/cilastatin (30/30 mg/kg,
imipenem group), or meropenem (20 mg/kg, meropenem group), every 8 h. The therapeutic efﬁcacy of
these agents was examined.
Results: A. baumannii strain Ab396 was susceptible to CMS only. However, meropenem treatment did
give a signiﬁcantly superior survival rate (100%) compared to treatment with imipenem (50%), CMS
(33%), or saline (0%) (p < 0.001 vs. the control and CMS groups, p = 0.006 vs. the imipenem group, by log-
rank test). Furthermore, compared to the other groups, the meropenem group demonstrated
signiﬁcantly more favorable results in terms of tissue penetration of the antibiotic, bacterial clearance,
normalization of the wet lung-to-body weight ratio, and down-regulation of pro-inﬂammatory cytokine
levels in the lungs.
Conclusions: Administration of meropenem via the respiratory tract proved to have the best therapeutic
efﬁcacy among the antibiotics tested when treating advanced murine CRAB pneumonia.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acinetobacter baumannii, a non-fermenting Gram-negative
bacterium found in the natural environment,1 is characterized
by its ability to develop resistance to a majority of antimicrobials,
and is an important nosocomial pathogen that is often involved in
hospital outbreaks.2,3 Patients with pneumonia due to carbape-
nem-resistant A. baumannii (CRAB) show a high mortality rate (30%
to 75%) and require prolonged hospital stays in intensive care units
(ICUs).4,5 Notwithstanding the fact that carbapenems have been* Corresponding author. Tel.: +886 6 2812811 ext. 52606; Fax: +886 6 2833351.
E-mail address: chiangsr@gmail.com (S.-R. Chiang).
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doi:10.1016/j.ijid.2011.09.015previously considered to be the gold standard drugs for severe A.
baumannii infection,6 nosocomial outbreaks caused by CRAB have
been increasingly reported worldwide.3,7 Handling such infections
is an ongoing clinical challenge. At present, parenteral colisti-
methate sodium (CMS) therapy is used as a salvage therapy for
multidrug-resistant (MDR) Gram-negative bacterial infections,8,9
and leads to a favorable clinical response in 55% to 74% of CRAB-
infected patients.10–12 However, Levin et al. reported that
parenteral CMS therapy achieved a good clinical response rate
in only 25% of patients with MDR bacterial pneumonia.13 Probably
pertinent is the poor tissue penetration of CMS based on the
ﬁndings of Montero et al., who reported that intraperitoneal CMS
had limited therapeutic efﬁcacy in CRAB pneumonia mice in
comparison with imipenem or sulbactam.14 As CRAB pneumoniases. Published by Elsevier Ltd. All rights reserved.
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tract has become attractive as an adjunctive therapy for CRAB
pneumonia patients,15,16 due to the high local drug concentrations
and low systemic toxicity.17,18 In a comparative cohort study, the
outcome of adjunctive inhaled CMS on ventilator-associated
pneumonia (VAP) was better than parenteral CMS alone.19
Traditionally, systemically circulated antimicrobials have been
used to treat pneumonia patients. However, administering
antibiotics via the respiratory tract, an adjunctive therapy, is an
interesting approach to treating pneumonia caused by MDR
organisms because of the clinical threat of these bacteria.20,21 A
meta-analysis indicated that intratracheal (i.t.) or aerosolized
antibiotic therapy may be useful when treating nosocomial
pneumonia.22 Additionally, the American Thoracic Society/Infec-
tious Diseases Society of America guidelines state that aerosolized
antibiotics combined with systemically administered antibiotics
may have some advantages when treating some MDR pathogens23
in VAP patients. Moreover, monotherapy with nebulized CMS may
be an attractive option when treating MDR Gram-negative
pneumonia in clinical practice24 or in animal studies.25 In addition,
it has been shown that there is a better therapeutic outcome after
treatment with i.t. colistin sulfate than when the drug is
administered intraperitoneally; this was demonstrated in our
murine model of early CRAB pneumonia, which involved analysis
at 2 h after intratracheal inoculation with a CRAB isolate.26
However, penetration of antibiotics in the distal lungs may be
hindered by bronchial plugs from the purulent secretions during
advanced pneumonia,25,27,28 and because of the poor tissue
penetration of CMS, the topical administration of CMS may have
only a limited therapeutic efﬁcacy in advanced CRAB pneumonia.
Moreover, the effectiveness of antibiotics administered via the
respiratory tract for the treatment of CRAB pneumonia has not
been extensively evaluated. Thus, it would be helpful to ﬁnd an
optimal antibiotic for treating advanced CRAB pneumonia via the
respiratory tract. Parenteral carbapenems have been considered to
be effective drugs when treating A. baumannii infections. Badia
et al. reported that intratracheal administration of imipenem was
able to achieve high local drug concentrations and thus has
potential when treating VAP caused by MDR Gram-negative
bacteria.29 Hence, like CMS, the administration of carbapenems via
the respiratory tract might be a potential therapy for CRAB
pneumonia. Therefore, in this study we compared the therapeutic
efﬁcacy of i.t. CMS, imipenem/cilastatin, and meropenem when
treating CRAB pneumonia (4 h after intratracheal inoculation with
a CRAB isolate) in mice.
2. Materials and methods
2.1. Microorganism and antibiotics
A. baumannii strain Ab396 was isolated from the bloodstream of
a clinical patient, and identiﬁed by the Phoenix 100 (Baxter Health
Care, USA). All aliquots were prepared and frozen at 80 8C until
used. Standard CMS powder was obtained from TTY Biopharm
(Taoyuan, Taiwan). Colistin sulfate was purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Imipenem was obtained from
Merck (Virginia, USA). Meropenem was supplied by Dainippon
Sumitomo, Osaka, Japan.
2.2. Determination of minimum inhibitory concentrations (MICs)
MIC values for colistin sulfate, meropenem, and imipenem for A.
baumannii strain Ab396 were determined by the agar dilution
method, and MIC interpretive breakpoints were identiﬁed follow-
ing the recommendations of the Clinical and Laboratory Standards
Institute.302.3. Mice
Six- to eight-week-old inbred BALB/c female mice weighing 20–
22 g, purchased from the Animal Center of the National Science
Council, Taipei, Taiwan, were allowed to equilibrate for 5–7 days at
the Animal Center of Chi Mei Medical Center. Food and water were
supplied ad libitum, light was controlled to provide 12-h day-and-
night periods, and the room air was HEPA ﬁlter-puriﬁed.
2.4. Mouse model for acute pneumonia
The acute pneumonia model was established in mice, as
previously described.26 In brief, the mice were anesthetized with
sodium pentobarbital at a dose of 70 mg/kg, and were supported in
a frame. The airway was illuminated externally by a lamp and the
vocal folds were exposed. A micropipette was passed down the
pharynx, and its tip was inserted between the vocal folds. At this
point 50 ml of a bacterial suspension containing 2.5  107 colony-
forming units (CFU) of bacteria and 10% porcine mucin was
instilled. The animal was maintained in an upright position for
2 min to allow the suspension to drain into the respiratory trees.
Based on the pulmonary pathology results of our previous study,26
in which acute pneumonia developed at 4 h after bacterial
instillation, treatment with the antimicrobial agents was initiated
at this time point. All animal experiments were approved by the
Chi Mei Medical Center Animal Center. Four cohorts of mice,
namely the control, CMS, imipenem, and meropenem groups, were
used during the following experiments.
2.5. Survival study
Since no dosing regimens with respect to an appropriate i.t. dose
for mice are available, the i.t. dosages chosen followed the parenteral
dosages as previously described.14,31,32 For each group, 12 infected
mice at 4 h after i.t. A. baumannii strain Ab396 inoculation were
treated i.t. with 25 ml of either 0.85% saline (control group), or
imipenem/cilastatin (30/30 mg/kg, imipenem group), or CMS
(166 666 U/kg, CMS group), or meropenem (20 mg/kg, meropenem
group), every 8 h for 48 h. The survival rates were recorded every
12 h until 72 h after i.t. A. baumannii strain Ab396 inoculation.
2.6. Pulmonary bacterial clearance, cytokines, and wet lung-to-body
weight ratios
The mice with CRAB pneumonia were treated with one of three
drugs or saline, as in the above survival study. After treatments
began, eight surviving mice that were tested at 24 h, 48 h (n = 8 for
each group), and 72 h (n = 8 for the imipenem, CMS, and
meropenem groups) were identiﬁed and sacriﬁced by an overdose
of intraperitoneal pentobarbital. After being weighed, homoge-
nized lung samples were examined to measure the pulmonary
bacterial load. Ten-fold serial dilutions of the homogenized lungs
were resuspended in saline, and 0.1 ml of each dilution was spread
on agar plates. The bacterial colonies growing in the plates were
counted and the results expressed as log10 CFU/mg of homoge-
nized lung at 24, 48, and 72 h. The lower limit of detection was 1.5
log10 CFU/mg. The lung samples were also examined for the wet
lung-to-body weight ratio at 24, 48, and 72 h.
In order to measure the cytokine levels in bronchoalveolar
lavage ﬂuid (BALF), eight surviving mice at 24 h, 48 h (n = 8 for each
group), and 72 h (n = 8 for the imipenem, CMS, and meropenem
groups) were separated from each group and sacriﬁced with an
intraperitoneal dose of 70 mg/kg of pentobarbital. The trachea of
each infected mouse was cannulated with a 25-gauge needle and
1 ml of 0.85% saline was infused into the lungs via the needle. After
this process, about 0.95 ml of BALF specimen was obtained by
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Figure 1. Survival rate. Kaplan–Meier survival curves for the mice with
carbapenem-resistant Acinetobacter baumannii pneumonia who received
intratracheal administration of meropenem, imipenem, colistimethate sodium,
or 0.85% saline, up to 72 h. The results are expressed as the cumulative survival rate
of 12 mice for each group. The meropenem group showed the highest survival rate.
(*Signiﬁcantly higher survival rate than that of the other groups.).
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Figure 2. Pulmonary bacterial clearance. Pulmonary bacterial numbers in mice with
carbapenem-resistant Acinetobacter baumannii pneumonia who received
intratracheal antibiotics up to 72 h. The results are expressed as mean values 
standard deviations of eight mice at each time point. The meropenem group showed
the lowest bacterial titers. (*Signiﬁcantly lower bacterial titer than that of the control
group at 48 h; #signiﬁcantly lower bacterial titer than that of the imipenem and
colistimethate sodium groups at 72 h.).
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measured in the BALF, including tumor necrosis factor-a (TNF-a),
interleukin-1b (IL-1b), interleukin-6 (IL-6), and macrophage
inﬂammatory protein 2 (MIP-2). This was done by ELISA kit
(R&D Systems, Minneapolis, MN, USA).
2.7. Pharmacokinetics of i.t. antibiotics in BALF and serum
The pharmacokinetics of the three tested drugs in the BALF
were determined after i.t. inoculation of a single dose of each
antibiotic. In each group, 30 healthy mice received i.t. 25 ml of
imipenem/cilastatin (30/30 mg/kg), meropenem (20 mg/kg), or
CMS (166 666 U/kg). At 0, 0.5, 1, 2, 4, and 6 h (n = 5 for each time
point) later, blood samples were obtained from anesthetized mice
by cardiac puncture before the BALF collection. The concentrations
of colistin sulfate, imipenem, and meropenem in the BALF and
serum were measured by bioassay utilizing Escherichia coli ATCC
25922.33 Since in vivo CMS is hydrolyzed into colistin sulfate,34 the
bioassay method will detect the concentrations and antibacterial
activity of colistin sulfate, rather than CMS itself.35 The lower limit
for detection of colistin sulfate was 0.5 mg/ml, for imipenem was
2 mg/ml, and for meropenem was 0.5 mg/ml. As the antibiotics
were administered via the respiratory tract, the tissue penetration
capability of the i.t. CMS, imipenem, and meropenem were
evaluated by comparing the serum-to-BALF concentration ratio.
2.8. Statistical analysis
Bacterial counts, wet lung-to-body weight ratios, cytokine
levels, and mortality rates were compared between the four study
groups at 48 h and between the three study groups at 72 h. Means
and medians are shown in order to describe the main trends.
Standard deviations and ranges are used to describe the data
dispersion. The Kruskal–Wallis H test and the Dunn method were
used for comparisons. p-Values of < 0.0083 at 48 h and <0.0167 at
72 h were considered statistically signiﬁcant for the post-hoc
comparisons according to the Bonferroni correction rule. Survival
rates were compared by log rank test. The dataset was analyzed
using SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Minimum inhibitory concentrations (MICs)
A. baumannii strain Ab396 was resistant to imipenem (MIC
128 mg/ml) and meropenem (MIC 32 mg/ml), but susceptible to
colistin sulfate (MIC 2 mg/ml). The details of A. baumannii strain
Ab396 have previously been published.26
3.2. Survival rates of mice with CRAB pneumonia
The survival rates of mice with A. baumannii strain Ab396
pneumonia in the control, CMS, imipenem, and meropenem groups
were 0%, 33.3%, 50%, and 100%, respectively, at 72 h after inoculation
(Figure 1). Of note, the meropenem group had the highest survival
rate and this was signiﬁcantly higher than that of the other three
groups (p < 0.001, meropenem vs. control and CMS groups;
p = 0.006, meropenem vs. imipenem group, by log-rank test).
To avoid biased results related to bacterial variations in antibiotic
susceptibility, 40 mice with pneumonia caused by another CRAB
isolate, A. baumannii strain Ab2006 (MICs: 32 mg/ml for imipenem,
64 mg/ml for meropenem, and 2 mg/ml for colistin sulfate), were
studied using the same protocol. There were 10 mice in each group.
Again, the mice treated with i.t. meropenem showed a higher
survival rate than those treated with i.t. imipenem or CMS therapy
(meropenem group 100%, imipenem group 70%, CMS group 0%,control group 0%, at 72 h after inoculation; p = 0.024 meropenem vs.
imipenem group, p < 0.001 meropenem vs. CMS group, and
p < 0.001 meropenem vs. control group, by log-rank test).
3.3. Pulmonary bacterial clearance of CRAB pneumonia treated with
the i.t. antibiotics
Data on bacterial clearance were obtained by examining the
homogenized lungs and are shown in Figure 2. Mice in the control
group showed increasing pulmonary bacterial loads from 24 to 48 h
after treatment, and all of the infected mice died between 48 and 72 h
post-infection. Mice in the imipenem and CMS groups showed only
slightly decreased pulmonary bacterial loads from 24 to 72 h after
treatment. In the meropenem group, the pulmonary bacterial counts
were signiﬁcantly reduced at 72 h. Pulmonary bacterial clearance in
the meropenem and imipenem groups were signiﬁcantly lower than
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Figure 3. Wet lung-to-body weight ratios. The wet lung-to-body weight ratios of
the mice with carbapenem-resistant Acinetobacter baumannii pneumonia who
received intratracheal antibiotics up to 72 h after infection. The results are
expressed as mean values  standard deviations of eight mice at each time point. The
meropenem group showed the lowest ratios. (*Signiﬁcantly lower ratio than that of the
control group at 48 h; #signiﬁcantly lower ratio than that of the imipenem and
colistimethate sodium groups at 72 h.).
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p < 0.001; imipenem vs. control group, p = 0.01). However, bacterial
clearance in the meropenem group only was signiﬁcantly lower than
that in the imipenem and CMS groups at 72 h (p = 0.016, meropenem
vs. imipenem group; and p = 0.002, meropenem vs. CMS group,
Kruskal–Wallis H test and Dunn test).
3.4. Wet lung-to-body weight ratios in lungs treated with i.t.
antibiotics
The sequential changes in the wet lung-to-body weight ratios of
the mice after i.t. antibiotic therapy are shown in Figure 3. All three
antibiotic groups had lower ratios than the control group at 24 and
48 h. However the meropenem group showed the lowest ratio at
72 h. The ratios in the meropenem and imipenem groups were
signiﬁcantly lower than that of the control group at 48 h
(p < 0.001, meropenem vs. control group; p = 0.001, imipenem
vs. control group, respectively), but the ratios in the meropenem
group were signiﬁcantly lower than the imipenem and CMS groups
at 72 h (p < 0.001, meropenem vs. imipenem group; p = 0.009,
meropenem vs. CMS group, Kruskal–Wallis H test and Dunn test).
3.5. Cytokine proﬁles in BALF of mice with CRAB pneumonia
The disparate effects of the i.t. antibiotics on TNF-a, IL-6, IL-1b,
and MIP-2 levels in BALF are shown in Figure 4. The control group72 h48 h24 h
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Figure 4. Cytokine proﬁles in the bronchoalveolar lavage ﬂuid. (a) Tumor necrosis factor alpha (TNF-a); (b) macrophage inﬂammatory protein 2 (MIP-2); (c) interleukin-1b
(IL-1b), (d) interleukin-6 (IL-6), levels in the bronchoalveolar ﬂuid of the control and intratracheal antibiotic-treated groups at 24–72 h. The results are expressed as mean
values  standard deviations of eight mice at each time point. The meropenem group showed the lowest levels. (*Signiﬁcantly lower cytokine level than that of the control group at
48 h; #signiﬁcantly lower cytokine level than that of the imipenem and colistimethate sodium groups at 72 h (except meropenem vs. imipenem group for IL-1b).).
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Ab396 infection. In contrast, a decline in cytokine levels after i.t.
antibiotic therapy was noted in the other groups, especially in the
meropenem group. Only in the meropenem group were the four
cytokine levels signiﬁcantly lower than in the control group at 48 h
(IL-1b, p = 0.003; IL-6, p = 0.002; TNF-a, p < 0.001; MIP-2,
p < 0.001), and the levels in the meropenem group were
signiﬁcantly lower than in the imipenem and CMS groups at
72 h (meropenem vs. imipenem group: TNF-a, p < 0.001; IL-6,
p = 0.004; MIP-2, p < 0.001; meropenem vs. CMS group: TNF-a,
p = 0.011; IL-6, p = 0.003; IL-1b, p = 0.002; MIP-2, p = 0.009;
Kruskal–Wallis H test, followed by Dunn test).
3.6. Pharmacokinetics of antibiotics in BALF and serum
The pharmacokinetics of the i.t. antibiotic concentrations in the
BALF are shown in Figure 5. Of note, both the imipenem and
meropenem concentrations declined promptly, after peak concen-
trations of 491.2 and 151.4 mg/ml, respectively, at 0 h. The
concentrations were 2.8 and 7.0 mg/ml at 2 h, respectively
(Figure 5, a and b). In contrast, the concentration of colistin sulfate
peaked at 1 h at 3.21  0.87 mg/ml (Figure 5c). Importantly, all drug
levels in the BALF were higher than the respective MICs for A. baumannii
strain Ab396 within 1 h. Conversely, the serum concentration of
colistin sulfate was undetectable at all time points, and the peak serum
concentrations of meropenem and imipenem at 0.5 h were 7.7 mg/mlTime (h)
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Figure 5. Pharmacokinetic proﬁles of the various antibiotics in the bronchoalveolar lav
bronchoalveolar ﬂuid and serum of healthy mice after intratracheal instillation of one do
mice in each group), and (d) the time course of the serum-to-bronchoalveolar lavage ﬂ
sodium group throughout, and the meropenem group had the highest tissue penetration
sodium (colistin sulfate) within 1 h.).and 15.61 mg/ml, respectively. From this it can be concluded that all
serum concentrations after i.t. antibiotic were lower than their
respective MICs for A. baumannii strain Ab396 at all time points.
3.7. Serum-to-BALF concentration ratio of antibiotics
The serum-to-BALF concentration ratio was used in this study
as an indicator of the tissue penetration capacity of the antibiotic
(Figure 5d). The optimal antibiotic efﬁcacy is evidenced when there
is early tissue distribution that achieves a high bactericidal
efﬁciency. It should be noted that both meropenem and imipenem
showed low plateau concentrations in the BALF beyond 2 h. Thus,
in the present study, early tissue penetration was deﬁned as the
serum-to-BALF concentration ratio within the ﬁrst 1 h.
The results showed that the meropenem group had the highest
serum-to-BALF concentration ratio compared to the imipenem
group and the CMS group at 0.5 h (7.2  2.6%, 4.9  1.2%, and 0%,
respectively) and at 1 h (8.8  3.1%, 4.7  1.3%, and 0%, respectively).
The ratios in the meropenem group were signiﬁcantly higher than
those in the CMS group (p < 0.001 vs. CMS group at 0.5 and 1 h;
Kruskal–Wallis H test followed by Dunn test). However, the
difference in these ratios between the meropenem and the imipenem
groups did not reach signiﬁcance (p = 0.077 vs. imipenem group at 0.5
and at 1 h; Kruskal–Wallis H test followed by Dunn test). Conceivably,
meropenem diffused more rapidly into the intravascular areas than
did the other antibiotics.Time (h)
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In the present study, i.t. meropenem had the best therapeutic
efﬁcacy in the treatment of acute murine CRAB pneumonia. In view
of the limited therapeutic efﬁcacy in relation to CRAB pneumonia
using intravenous CMS therapy,13 this ﬁnding may be of crucial
clinical relevance. This is because this pathogen is a major cause of
nosocomial infections and there are very few antibiotic options
available to treat these types of infection in ICUs globally.7,36
Meropenem and imipenem have similar antimicrobial activities
against A. baumannii strains both in vitro37 and clinically.38
However, in the present study, the superior therapeutic efﬁcacy of
i.t. meropenem was clearly identiﬁed. The better therapeutic
efﬁcacy of i.t. meropenem is mirrored by the favorable results for
bactericidal efﬁciency, normalization of the wet lung-to-body
weight ratios, and declines in BALF TNF-a, IL-6, IL-1b, and MIP-2
levels.
Furthermore, i.t. CMS therapy, when used to treat A. baumannii
strain Ab396-infected mice was inferior to i.t. meropenem
treatment. This contrasts with the 100% survival rate of mice
with early CRAB pneumonia (2 h after intratracheal inoculation
with a Ab396 isolate) post i.t. colistin sulfate therapy in our
previous experiments.26 Experimental severe bronchopneumonia
and human VAP are characterized by the presence of multiple
purulent plugs obstructing the distal bronchioles,28,39 which could
markedly impair lung deposition of antibiotics administered via
the respiratory tract.25,28 Thus, the unfavorable outcome of i.t. CMS
may be a result of poor tissue penetration, as evidenced in our
results (Figure 5d). In addition, CMS displayed little antibacterial
activity in our study. This may be because the transformation of
CMS into colistin sulfate is a prerequisite for its antibacterial
activity34 both in vitro40 and in vivo.41 A slow transformation of
CMS into colistin sulfate in the BALF may be the cause of the
limited efﬁcacy of i.t. CMS (Figure 5c). This is consistent with a
previous report where it was shown that only 20% of CMS was
hydrolyzed to colistin sulfate in plasma and isotonic phosphate
buffer within 4 h.40
The precise mechanisms of antibiotic penetration into the lungs
after administration via the respiratory tract are not well
understood. The pharmacokinetics of antibiotics in blood, bron-
chial secretions, lung tissue, and urine have been investigated in
detail.42–44 However, antibiotic concentrations in bronchial
secretions are not truly representative of the concentrations in
severely infected lung parenchyma, where there may be marked
impairment of the tissue penetration of the antibiotic. It is possible
that the tissue concentration in the lung parenchyma is the main
determinant of bactericidal efﬁciency.44 There are methodological
limitations to lung tissue sampling in humans and animals and
therefore the one reliable method available to measure the tissue
penetration of antibiotics may be assaying serum concentrations
as a measure of lung diffusion efﬁcacy.42
In the present study, the concentration changes of the antibiotic
in the BALF were assayed to indicate the tissue penetration of the
antibiotic. One would expect the pharmacokinetic studies to show
the initial concentrations in the BALF of the i.t. antibiotics to be the
highest, with these concentrations then decreasing in a manner
correlated with tissue penetration. Both the meropenem curve and
the imipenem curve revealed the same initially steeply declining
slope, in contrast with the gradually increasingly steep curve of
colistin sulfate (Figure 5, a–c). This ﬁnding indicates the rapid
tissue distribution of meropenem and imipenem, while CMS has
limited tissue penetration only. Furthermore, the serum-to-BALF
concentration ratios were also assessed to investigate the efﬁcacy
of tissue penetration. The results demonstrated undetectable
levels of colistin sulfate derived from CMS in serum, while
meropenem yielded the highest serum-to-BALF concentrationratio (Figure 5d) within 1 h, the critical period for early infection.
Thus, meropenem may have a faster tissue distribution than
imipenem and CMS, which will help with early bacterial
eradication. This agrees with a previous report, which showed
that meropenem had a more rapid penetration into the central
nervous system than imipenem.45
Our study has several limitations. Firstly, the volume and
architecture of the lungs in mice are different from those in
humans, and the uneven distribution of antibiotics by the i.t.
method may be clinically relevant. Secondly, in the present study,
the pharmacokinetics were derived from healthy mice and these
results may be different from those of infected mice. Thirdly, only a
single strain of MDR Acinetobacter was tested and therefore the
results cannot be extrapolated to infections by other strains, which
possibly possess different mechanisms of resistance. Finally,
pharmacokinetics in mice and humans are different,46 thus the
corresponding human doses and adverse reactions associated with
the topical administration need to be investigated in clinical trials.
Clinical extrapolation of the current results should be made with
great caution, and in particular, the use of meropenem or
imipenem may not be recommended in the presence of
carbapenemase-producing pathogens. In conclusion, in our model,
i.t. administration of meropenem exhibited signiﬁcant therapeutic
efﬁcacy when treating CRAB pneumonia in mice, in terms of
survival rate, bacterial clearance in pulmonary parenchyma,
normalization of wet lung-to-body weight ratio, and down-
regulation of BALF proinﬂammatory cytokine levels. The role of
i.t. meropenem in the treatment of CRAB pneumonia merits further
clinical investigation.
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